412 related articles for article (PubMed ID: 31486522)
1. Daratumumab for relapsed or refractory AL amyloidosis with high plasma cell burden.
Schwotzer R; Manz MG; Pederiva S; Waibel C; Caspar C; Lerch E; Flammer AJ; Brouwers S; Seeger H; Heimgartner R; Fehr T; Rossi D; Bianchi E; Stüssi G; Ghilardi G; Gerber B
Hematol Oncol; 2019 Dec; 37(5):595-600. PubMed ID: 31486522
[TBL] [Abstract][Full Text] [Related]
2. Daratumumab for relapsed AL amyloidosis-When cumulative real-world data precedes clinical trials: A multisite study and systematic literature review.
Shragai T; Gatt M; Lavie N; Vaxman I; Tadmor T; Rouvio O; Zektser M; Horowitz N; Magen H; Ballan M; Suru C; Luttwak E; Levi S; Ziv-Baran T; Avivi I; Cohen YC
Eur J Haematol; 2021 Feb; 106(2):184-195. PubMed ID: 33090552
[TBL] [Abstract][Full Text] [Related]
3. A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis.
Roussel M; Merlini G; Chevret S; Arnulf B; Stoppa AM; Perrot A; Palladini G; Karlin L; Royer B; Huart A; Macro M; Morel P; Frenzel L; Touzeau C; Boyle E; Dorvaux V; Le Bras F; Lavergne D; Bridoux F; Jaccard A
Blood; 2020 Apr; 135(18):1531-1540. PubMed ID: 32108228
[TBL] [Abstract][Full Text] [Related]
4. High rate of profound clonal and renal responses with daratumumab treatment in heavily pre-treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate.
Milani P; Fazio F; Basset M; Berno T; Larocca A; Foli A; Riva M; Benigna F; Oliva S; Nuvolone M; Rodigari L; Petrucci MT; Merlini G; Palladini G
Am J Hematol; 2020 Aug; 95(8):900-905. PubMed ID: 32282971
[TBL] [Abstract][Full Text] [Related]
5. Treatment with daratumumab in patients with relapsed/refractory AL amyloidosis: a multicentric retrospective study and review of the literature.
Lecumberri R; Krsnik I; Askari E; Sirvent M; González-Pérez MS; Escalante F; Pradillo V; Tamariz LE; Cánovas V; Alegre A; Gironella M; González-García ME; Infante MS; Lakhwani S; Martínez-Bilbao C; Dourdil V; Ramírez-Payer Á; Sarrá J; Cibeira MT
Amyloid; 2020 Sep; 27(3):163-167. PubMed ID: 32106714
[TBL] [Abstract][Full Text] [Related]
6. Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study.
Sanchorawala V; Sarosiek S; Schulman A; Mistark M; Migre ME; Cruz R; Sloan JM; Brauneis D; Shelton AC
Blood; 2020 Apr; 135(18):1541-1547. PubMed ID: 31978210
[TBL] [Abstract][Full Text] [Related]
7. Rapid response to single agent daratumumab is associated with improved progression-free survival in relapsed/refractory AL amyloidosis.
Cohen OC; Brodermann MH; Blakeney IJ; Mahmood S; Sachchithanantham S; Ravichandran S; Law S; Lachmann HJ; Whelan CJ; Popat R; Rabin N; Yong K; Kyriakou C; Shah R; Cheesman S; Worthington S; Hawkins P; Gillmore JD; Wechalekar AD
Amyloid; 2020 Sep; 27(3):200-205. PubMed ID: 32408823
[No Abstract] [Full Text] [Related]
8. Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria.
Kimmich CR; Terzer T; Benner A; Dittrich T; Veelken K; Carpinteiro A; Hansen T; Goldschmidt H; Seckinger A; Hose D; Jauch A; Wörner S; Beimler J; Müller-Tidow C; Hegenbart U; Schönland SO
Blood; 2020 Apr; 135(18):1517-1530. PubMed ID: 32107537
[TBL] [Abstract][Full Text] [Related]
9. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
Kastritis E; Palladini G; Minnema MC; Wechalekar AD; Jaccard A; Lee HC; Sanchorawala V; Gibbs S; Mollee P; Venner CP; Lu J; Schönland S; Gatt ME; Suzuki K; Kim K; Cibeira MT; Beksac M; Libby E; Valent J; Hungria V; Wong SW; Rosenzweig M; Bumma N; Huart A; Dimopoulos MA; Bhutani D; Waxman AJ; Goodman SA; Zonder JA; Lam S; Song K; Hansen T; Manier S; Roeloffzen W; Jamroziak K; Kwok F; Shimazaki C; Kim JS; Crusoe E; Ahmadi T; Tran N; Qin X; Vasey SY; Tromp B; Schecter JM; Weiss BM; Zhuang SH; Vermeulen J; Merlini G; Comenzo RL;
N Engl J Med; 2021 Jul; 385(1):46-58. PubMed ID: 34192431
[TBL] [Abstract][Full Text] [Related]
10. Daratumumab for the treatment of AL amyloidosis.
Sidiqi MH; Gertz MA
Leuk Lymphoma; 2019 Feb; 60(2):295-301. PubMed ID: 30033840
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy and safety of daratumumab in the treatment of advanced light chain amyloidosis].
Shen KN; Miao HL; Gao YJ; Cao XX; Zhou DB; Su W; Li J
Zhonghua Xue Ye Xue Za Zhi; 2022 Jan; 43(1):31-34. PubMed ID: 35231990
[No Abstract] [Full Text] [Related]
12. [Daratumumab for the treatment of primary systemic amyloidosis: a multicenter retrospective analysis].
Liu Y; Huang XH; Duan WB; Fang BJ; Huang DP; Zhang YH; Xu L; Zhang HY; Zhang H; Wen L; Huang XJ; Lu J
Zhonghua Nei Ke Za Zhi; 2021 Nov; 60(11):987-992. PubMed ID: 34689520
[No Abstract] [Full Text] [Related]
13. Successful Treatment of Systemic Light Chain Amyloidosis with Liver Involvement using Low-Frequency Daratumumab: A Case Report.
Meng X; He J; Cheng F; Yan H; Zhu C; Guo X; Li Y; Cai Z; He D
Am J Case Rep; 2024 Jan; 25():e942534. PubMed ID: 38229422
[TBL] [Abstract][Full Text] [Related]
14. Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma.
Zhang T; Wang S; Lin T; Xie J; Zhao L; Liang Z; Li Y; Jiang J
Oncotarget; 2017 May; 8(20):34001-34017. PubMed ID: 28454113
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Daratumumab-based Regimens in Pretreated Light Chain (AL) Amyloidosis: A Systematic Review.
Ehsan H; Rafae A; Masood A; Wahab A; Sana MK; Ansar I; Neupane K; Umar A; Ehsan A; Hashmi H
Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):e285-e292. PubMed ID: 34879994
[TBL] [Abstract][Full Text] [Related]
16. [Interest of daratumumab in refractory AL amyloidosis in a 96-year-old patient].
Vial G; Lafargue A; Mercié P; Duffau P; Ribeiro E
Rev Med Interne; 2022 Nov; 43(11):673-676. PubMed ID: 35934598
[TBL] [Abstract][Full Text] [Related]
17. Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma.
Chari A; Lonial S; Mark TM; Krishnan AY; Stockerl-Goldstein KE; Usmani SZ; Londhe A; Etheredge D; Fleming S; Liu B; Ukropec J; Lin TS; Jagannath S; Nooka AK
Cancer; 2018 Nov; 124(22):4342-4349. PubMed ID: 30395359
[TBL] [Abstract][Full Text] [Related]
18. Organ responses with daratumumab therapy in previously treated AL amyloidosis.
Chung A; Kaufman GP; Sidana S; Eckhert E; Schrier SL; Lafayette RA; Arai S; Witteles RM; Liedtke M
Blood Adv; 2020 Feb; 4(3):458-466. PubMed ID: 32027745
[TBL] [Abstract][Full Text] [Related]
19. Dual Monoclonal Antibody Therapy in Patients With Systemic AL Amyloidosis and Cardiac Involvement.
Godara A; Siddiqui NS; Lee LX; Toskic D; Fogaren T; Varga C; Comenzo RL
Clin Lymphoma Myeloma Leuk; 2020 Mar; 20(3):184-189. PubMed ID: 31983636
[TBL] [Abstract][Full Text] [Related]
20. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA.
Palladini G; Kastritis E; Maurer MS; Zonder J; Minnema MC; Wechalekar AD; Jaccard A; Lee HC; Bumma N; Kaufman JL; Medvedova E; Kovacsovics T; Rosenzweig M; Sanchorawala V; Qin X; Vasey SY; Weiss BM; Vermeulen J; Merlini G; Comenzo RL
Blood; 2020 Jul; 136(1):71-80. PubMed ID: 32244252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
